Erythropoiesis-stimulating agents—benefits and harms in the treatment of anemia in cancer patients
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Erythropoiesis-stimulating agents—benefits and harms in the treatment of anemia in cancer patients ; day:28 ; month:8 ; year:2023 ; pages:1-4
Magazine of European Medical Oncology ; (28.8.2023), 1-4
- Creator
-
Heregger, Ronald
Greil, Richard
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12254-023-00902-4
- URN
-
urn:nbn:de:101:1-2023110711152621413218
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:44 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Heregger, Ronald
- Greil, Richard
- SpringerLink (Online service)
Other Objects (12)
Tips for erythropoiesis-stimulating agent treatment of renal anemia
Lessons from clinical trials with erythropoiesis-stimulating agents (ESAs)
Erythropoiesis stimulating agents and reno-protection: a meta-analysis
Anemia and iron deficiency in COPD patients: prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron
Resistance to Erythropoiesis-Stimulating Agents among Patients on Hemodialysis Is Typically Transient
Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study
Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors
The effect of erythropoiesis‑stimulating agents on lung cancer patients: a meta‑analysis
Impact of anemia requiring transfusion or erythropoiesis-stimulating agents on new-onset cardiovascular events and mortality after continuous renal replacement therapy
Role of circulating endothelial progenitors in responsiveness to erythropoiesis-stimulating agents in hemodialysis patients
In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study
Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial
Tips for erythropoiesis-stimulating agent treatment of renal anemia
Lessons from clinical trials with erythropoiesis-stimulating agents (ESAs)
Erythropoiesis stimulating agents and reno-protection: a meta-analysis
Anemia and iron deficiency in COPD patients: prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron
Resistance to Erythropoiesis-Stimulating Agents among Patients on Hemodialysis Is Typically Transient
Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study
Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors
The effect of erythropoiesis‑stimulating agents on lung cancer patients: a meta‑analysis
Impact of anemia requiring transfusion or erythropoiesis-stimulating agents on new-onset cardiovascular events and mortality after continuous renal replacement therapy
Role of circulating endothelial progenitors in responsiveness to erythropoiesis-stimulating agents in hemodialysis patients
In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study
Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial
Tips for erythropoiesis-stimulating agent treatment of renal anemia
Lessons from clinical trials with erythropoiesis-stimulating agents (ESAs)
Erythropoiesis stimulating agents and reno-protection: a meta-analysis
Anemia and iron deficiency in COPD patients: prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron
Resistance to Erythropoiesis-Stimulating Agents among Patients on Hemodialysis Is Typically Transient
Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study
Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors
The effect of erythropoiesis‑stimulating agents on lung cancer patients: a meta‑analysis
Impact of anemia requiring transfusion or erythropoiesis-stimulating agents on new-onset cardiovascular events and mortality after continuous renal replacement therapy
Role of circulating endothelial progenitors in responsiveness to erythropoiesis-stimulating agents in hemodialysis patients
In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study